

HAND DELIVERED OCTOBER 13, 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hastings *et al.*

Serial No.: TBA

Group Art Unit: TBA

Filed: Herewith

Examiner: TBA

Title: HUMAN NEURONAL
ATTACHMENT FACTOR-1

Attorney Docket No.: PF226D1



INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AB listed on the attached form PTO 1449.

Copies of references AA and AB were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 08/799,173, filed February 12, 1997, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 08/799,173 for copies of references AA and AB.

Polynucleotide sequences HLHCE24R, HLHDR83R and HPTSB36R, SEQ ID NOS:16, 17 and 18, respectively, are also disclosed as SEQ ID NOS:10,206; 506; and 6,911 in copending US Patent Application Serial Nos. 08/276,163, 08/345,704 and 08/196,362, respectively.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: October 13, 1998



Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 309-8504 (phone)

KKH/ur

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket No. (Optional) PF226D1	Application Number
	Applicant Hastings et al.	
	Filing Date 10/09/98	Group Art Unit

U.S. PATENT DOCUMENTS

<u>Examiner</u>	<u>Document Number</u>	<u>Date</u>	<u>Name</u>	<u>Class</u>	<u>SubCls</u>	<u>Filing Date</u>
AA	5,279,966	01/1994	Jessell et al.			

FOREIGN PATENT DOCUMENTS

<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class</u>	<u>SubCls</u>	<u>Translation</u> <u>Yes/No</u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Hillier, L., et al., GenBank Acces. No. T81066, March 15, 1995.

Examiner	Date Considered
-----------------	------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.